Minerva Surgical (NASDAQ:UTRS) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Minerva Surgical (NASDAQ:UTRS – Get Rating) announced its quarterly earnings results on Wednesday. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07), MarketWatch Earnings reports. Minerva Surgical updated its FY 2022 guidance to EPS.

UTRS stock opened at $1.75 on Friday. The business’s 50-day moving average is $4.06 and its two-hundred day moving average is $5.40. Minerva Surgical has a 1 year low of $1.64 and a 1 year high of $10.37. The company has a quick ratio of 2.60, a current ratio of 3.29 and a debt-to-equity ratio of 0.89.

Several analysts recently issued reports on the stock. Piper Sandler reduced their price objective on shares of Minerva Surgical from $12.00 to $6.00 in a report on Thursday. Zacks Investment Research lowered shares of Minerva Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.50.

Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Minerva Surgical in the 4th quarter valued at $54,000. Renaissance Technologies LLC purchased a new stake in Minerva Surgical in the fourth quarter valued at $78,000. BlackRock Inc. acquired a new position in Minerva Surgical in the fourth quarter valued at $88,000. Finally, Millennium Management LLC purchased a new position in shares of Minerva Surgical during the fourth quarter worth about $134,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Minerva Surgical Company Profile (Get Rating)

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

Further Reading